Research programme: adenosine A2A receptor agonists - Lewis and Clark Pharmaceuticals
Alternative Names: LNC-001 therapeuticsLatest Information Update: 28 Jul 2024
At a glance
- Originator Lewis and Clark Pharmaceuticals
- Class Analgesics; Antiglaucomas; Nucleosides
- Mechanism of Action Adenosine A2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Clostridium difficile infections; Diabetic foot ulcer; Diabetic nephropathies; Glaucoma; Graft-versus-host disease; Inflammatory bowel diseases; Pain; Sickle cell anaemia
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Autoimmune-disorders in USA (Topical)
- 28 Jul 2024 No recent reports of development identified for research development in Clostridium-difficile-infections in USA (Topical)
- 28 Jul 2024 No recent reports of development identified for research development in Diabetic-foot-ulcer in USA (Topical)